Zacks Research Issues Negative Forecast for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Zacks Research dropped their Q2 2025 EPS estimates for CRISPR Therapeutics in a research report issued on Monday, December 9th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.48) for the quarter, down from their previous forecast of ($1.47). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.17) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm earned ($1.41) EPS.

Other research analysts have also recently issued research reports about the company. Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 6th. Chardan Capital restated a "buy" rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a report on Wednesday. Royal Bank of Canada reissued a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of "Hold" and an average price target of $77.93.

CRISPR Therapeutics Stock Performance

CRSP stock traded down $1.93 during midday trading on Thursday, hitting $45.85. 1,293,249 shares of the stock were exchanged, compared to its average volume of 1,498,575. The stock's 50-day moving average price is $48.82 and its 200-day moving average price is $51.33. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of -16.88 and a beta of 1.62. CRISPR Therapeutics has a fifty-two week low of $43.42 and a fifty-two week high of $91.10.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. SFE Investment Counsel increased its holdings in CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company's stock valued at $316,000 after purchasing an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock worth $249,000 after buying an additional 211 shares during the period. Boston Family Office LLC grew its stake in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after buying an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC raised its holdings in shares of CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after buying an additional 218 shares during the period. Finally, National Bank of Canada FI lifted its position in CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after acquiring an additional 220 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,382 shares of company stock valued at $2,744,179. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.